retatrutide efficacy clinical trials and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 VisualAbstract: Retatrutide reduces body weight

Foundayo is a once-daily pill classified as an oral small-molecule GLP-1 receptor agonist, with a different chemical structure from injectable GLP-1 drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), and from oral semaglutide (Rybelsus, the Wegovy pill), which belongs to the same peptide class as the injectables

Clin Ther (2012) 34:208290

These effects form the foundation of incretin-based obesity therapy and have been studied extensively since semaglutides approval in 2017

Based on the available data, tirzepatide has the lowest discontinuation rates and similar or slightly lower GI side effect rates compared to semaglutide

These symptoms can overlap with and potentially worsen the gastrointestinal effects already associated with GLP-1 therapy, making it difficult to distinguish which agent is responsible for adverse effects

Cagrilintide shows greater potency and a longer half-life (approximately 7 days) than earlier amylin analogs like Pramlintide, which is why its generating attention in the metabolic optimization space